Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosfomycin as an oral alternative treatment for acute bacterial prostatitis due to multidrug-resistant Escherichia coli (pilot study)
2019-003792-19Phase 4Active
- Sponsor
- MútuaTerrassa
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of fosfomycin in Acute Prostatitis (2 arms), sponsored by MútuaTerrassa. Primary endpoints: Clinical cure and Microbiological cure. Started Dec 2024; status: active.
02
Drugs
fosfomycin
03
Conditions
Acute Prostatitis
Beyond the preview
Go deeper on 2019-003792-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003792-19.